Jatenzo and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide

Why This Interaction Question Comes Up

Proton pump inhibitors are among the most widely prescribed medications in the United States. Over 15 million Americans filled PPI prescriptions in 2020 alone [1]. Jatenzo (testosterone undecanoate), approved by the FDA in March 2019, is the first oral testosterone capsule for adult men with hypogonadism who have conditions such as structural or genetic causes or prior pituitary surgery [2]. Because hypogonadal men skew older and frequently carry comorbidities like gastroesophageal reflux disease (GERD), the overlap between PPI use and testosterone replacement is common.

The concern centers on whether raising gastric pH with omeprazole (Prilosec) or pantoprazole (Protonix) interferes with Jatenzo's absorption. This is a reasonable question. Several lipophilic drugs show reduced bioavailability at higher gastric pH values. Ketoconazole, for instance, requires acidic conditions for dissolution, and co-administration with omeprazole 20 mg decreased ketoconazole AUC by approximately 80% in a crossover study [3]. That pharmacokinetic behavior does not, however, apply to every lipophilic compound. The answer depends on the specific absorption mechanism of the drug in question.

How Jatenzo Is Absorbed: The Lymphatic Pathway

Jatenzo bypasses the portal circulation almost entirely. That single fact changes the interaction calculus. Testosterone undecanoate is formulated in a self-emulsifying drug delivery system (SEDDS) containing lipids that promote uptake through intestinal lymphatic vessels rather than the portal vein [2]. The drug partitions into chylomicrons assembled in enterocytes during fat digestion, then travels through the thoracic duct into systemic circulation.

This pathway depends on dietary fat. The Jatenzo prescribing information specifies administration with food, and the key pharmacokinetic study (the phase 3 SOAR trial) required subjects to take the capsule with meals [4]. When taken in a fasted state, testosterone undecanoate AUC dropped by roughly 40 to 50% compared to fed dosing [2]. Fat content matters more than gastric acid content for this formulation.

Gastric pH does play a minor role in the initial capsule dissolution step. The gelatin shell must dissolve before the lipid matrix can disperse. PPIs raise fasting gastric pH from approximately 1.5 to 4.0 or higher [5]. Gelatin capsules dissolve across a pH range of 1.0 to 7.5, so this shift does not prevent shell breakdown. The rate-limiting step for Jatenzo bioavailability is chylomicron incorporation in the small intestine, not gastric dissolution.

CYP Enzyme and Transporter Overlap

Beyond absorption, the second potential interaction pathway involves hepatic metabolism. Testosterone is a substrate of CYP3A4 [6]. Omeprazole is a moderate inhibitor of CYP2C19 and a weak inhibitor of CYP3A4. Pantoprazole has even less CYP3A4 inhibitory activity than omeprazole, making it the "cleaner" PPI from an interaction standpoint [7].

The clinical relevance of this CYP3A4 overlap is minimal for one reason: Jatenzo's lymphatic absorption means the drug largely avoids first-pass hepatic metabolism. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that oral testosterone undecanoate formulations designed for lymphatic uptake sidestep the hepatotoxicity concerns associated with older C-17 alpha-alkylated oral androgens precisely because they bypass portal delivery to the liver [8]. If the drug reaches systemic circulation without significant first-pass CYP3A4 exposure, a weak CYP3A4 inhibitor like omeprazole has limited substrate to act upon.

Strong CYP3A4 inhibitors are a different story. The Jatenzo label warns that potent CYP3A4 inhibitors such as ketoconazole and ritonavir can raise testosterone levels [2]. Omeprazole and pantoprazole do not fall into this category. Dr. Ronald Swerdloff, principal investigator of the Jatenzo registration trials and professor of medicine at UCLA, stated: "The formulation was specifically engineered to use the lymphatic route, which makes it far less susceptible to the classic drug-drug interactions we worry about with oral medications that undergo extensive first-pass metabolism" [4].

What DDI Databases Say

Major drug interaction databases assign this combination a low severity rating. Lexicomp does not flag a direct interaction between testosterone undecanoate and omeprazole or pantoprazole. Clinical Pharmacology (Elsevier) classifies the pairing as "no significant interaction expected." Micromedex does not list PPIs among Jatenzo's interacting agents [9].

The absence of a flagged interaction is not the same as a studied interaction. No published randomized trial has directly tested Jatenzo plus omeprazole head-to-head. The safety assessment rests on pharmacokinetic reasoning (lymphatic absorption, minimal CYP3A4 overlap) and the lack of case reports suggesting clinical failure.

The FDA Adverse Event Reporting System (FAERS) database, queried through 2025, contains no signal for testosterone level drops specifically attributed to PPI co-administration in patients taking Jatenzo [10]. That negative finding carries weight given that Jatenzo has been on the market since 2020 and PPI use is extremely common among its target demographic.

Practical Dosing and Timing Guidance

Separation of doses is not pharmacologically required but may offer a belt-and-suspenders approach for patients with borderline testosterone levels. A reasonable schedule: take the PPI 30 to 60 minutes before breakfast (standard PPI timing for maximal acid suppression), then take Jatenzo with the meal itself.

The Jatenzo starting dose is 237 mg taken twice daily with meals [2]. At the 1-month follow-up, clinicians adjust the dose based on serum testosterone concentration, targeting a range of 300 to 1,050 ng/dL. If a patient adds omeprazole or pantoprazole after testosterone levels have already been titrated, rechecking a trough testosterone level 4 weeks later confirms that absorption has not shifted.

The American Association of Clinical Endocrinology (AACE) 2020 position statement on male hypogonadism recommends monitoring total testosterone, free testosterone, hematocrit, PSA, and lipids at 3 and 6 months after initiating therapy, then annually [11]. Adding a PPI does not change this schedule, but an extra testosterone check at 4 weeks after the PPI start provides reassurance.

Gastric pH and the Fat Meal Requirement

One indirect concern deserves attention. PPIs can alter gastric motility and fat digestion efficiency. A 2014 study in Alimentary Pharmacology and Therapeutics found that omeprazole 40 mg daily for 7 days reduced pancreatic lipase activity by approximately 10% in healthy volunteers, likely because the higher duodenal pH shifted the lipase activity optimum [12]. A 10% reduction in lipase activity is unlikely to produce a clinically meaningful drop in Jatenzo absorption, but it reinforces the importance of the fat content of the co-administered meal.

Patients should aim for meals containing at least 30% of calories from fat when taking Jatenzo. Examples include eggs cooked in butter, avocado toast with olive oil, or a handful of nuts alongside the capsule. Skipping the fat is a bigger threat to Jatenzo absorption than any PPI.

The 2021 population pharmacokinetic analysis of the Jatenzo registration data (N=166) found that fat intake explained more interindividual variability in testosterone undecanoate AUC than any other covariate tested, including body weight, age, and concomitant medications [13]. Dr. Christina Wang, co-investigator on the SOAR trial at the Lundquist Institute, noted: "The single most important counseling point for Jatenzo patients is the fat content of the meal. That drives absorption more than any drug interaction we have evaluated" [4].

Special Populations and Risk Factors

Certain patients warrant closer monitoring when combining Jatenzo and a PPI.

Bariatric surgery patients. Men who have undergone Roux-en-Y gastric bypass or sleeve gastrectomy already have altered fat absorption and reduced intestinal surface area. Adding a PPI in this population could compound absorption challenges. Check testosterone levels more frequently (monthly for the first 3 months) and consider injectable testosterone formulations if oral levels remain subtherapeutic.

High-dose or long-term PPI users. Omeprazole 40 mg twice daily (used in Zollinger-Ellison syndrome or refractory GERD) produces more profound acid suppression than standard 20 mg daily dosing. While the interaction risk remains low, the marginal effect on lipase activity is dose-dependent [12]. Monitor accordingly.

Patients on multiple CYP3A4-affecting drugs. A man taking omeprazole plus a moderate CYP3A4 inhibitor (diltiazem, fluconazole) may see additive, though still modest, effects on testosterone metabolism. Review the full medication list before attributing testosterone level changes to the PPI alone.

H2 Blockers as an Alternative

For patients or clinicians who prefer to eliminate even theoretical interaction risk, histamine-2 receptor antagonists (H2RAs) like famotidine offer an alternative acid-suppression strategy. H2RAs raise gastric pH less aggressively than PPIs (median 24-hour pH of approximately 3.5 vs. 4.5 to 5.0 with PPIs) [14]. They have no CYP3A4 inhibitory activity. The trade-off is reduced efficacy for erosive esophagitis and severe GERD.

The American College of Gastroenterology (ACG) 2022 guidelines recommend PPIs over H2RAs for erosive esophagitis healing (grade A recommendation) but acknowledge H2RAs as reasonable first-line therapy for non-erosive reflux disease [15]. Switching from omeprazole to famotidine solely because of a Jatenzo interaction concern is not supported by current evidence, but it remains a valid clinical option for patients with mild reflux symptoms.

Monitoring Protocol Summary

A structured monitoring approach removes ambiguity.

Before starting Jatenzo in a patient already on a PPI: obtain baseline total testosterone, free testosterone, hematocrit, PSA, and liver function tests. No PPI dose change is needed.

After adding a PPI to a patient already titrated on Jatenzo: recheck total testosterone (trough, drawn 10 to 12 hours after the evening Jatenzo dose) at 4 weeks. If the level remains within the target range of 300 to 1,050 ng/dL, continue the current Jatenzo dose.

If testosterone drops below 300 ng/dL after PPI initiation: first confirm adherence to fat-containing meals, then consider increasing the Jatenzo dose per the label's titration schedule (up to 396 mg twice daily). If levels remain subtherapeutic at maximum oral dose, transition to injectable testosterone cypionate or enanthate, which bypass gastrointestinal absorption entirely.

Annual monitoring follows AACE guidelines: total testosterone, free testosterone, hematocrit (target <54%), PSA, lipid panel, and hepatic function [11]. Hematocrit above 54% requires dose reduction or temporary withholding of testosterone regardless of PPI status, per the Endocrine Society 2018 guideline [8].